The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Open accessAbstract
Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The Genome of the Kinetoplastid Parasite, Leishmania major
Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M.-A., Adlem, E., Aert, R., et al. (2005) · Science · doi:10.1126/science.1112680 · Cited by 1,346
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
Comparative genomic analysis of three Leishmania species that cause diverse human disease
Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters, N., Adlem, E., Tivey, A., Aslett, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2053 · Cited by 768
Drug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Library, W. (2010) · Cited by 579
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Pentavalent Antimonials: New Perspectives for Old Drugs
Frézard, F., Demicheli, C., & Ribeiro, R. R. (2009) · Molecules · doi:10.3390/molecules14072317 · Cited by 496
(2010) · PubMed · Cited by 371
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Fischer, E., & Sauer, U. (2005) · Nature Genetics · doi:10.1038/ng1555 · Cited by 318
Genomic-scale prioritization of drug targets: the TDR Targets database
Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F. S., Campbell, R. K., Carmona, S., Carruthers, I. M., Chan, A. W. E., Chen, F., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2684 · Cited by 306
Roberts, C. W., McLeod, R., Rice, D. W., Ginger, M., Chance, M. L., & Goad, L. J. (2003) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(02)00280-3 · Cited by 296
Melby, P. C., Chandrasekar, B., Zhao, W., & Coe, J. E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1912 · Cited by 288
De Muylder, G., Ang, K. K. H., Chen, S., Arkin, M. R., Engel, J. C., & McKerrow, J. H. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001253 · Cited by 232
Molecular mechanisms of antimony resistance in Leishmania
Ashutosh, Sundar, S., & Goyal, N. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46841-0 · Cited by 222
In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs
Seifert, K., & Croft, S. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.73-79.2006 · Cited by 207
Pathak, M. K., & Yi, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3391 · Cited by 190
Immune response to leishmania: paradox rather than paradigm
Tripathi, P., Singh, V., & Naik, S. (2007) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2007.00311.x · Cited by 189
Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations
Sundar, S., Mehta, H., Suresh, A. V., Singh, S. P., Rai, M., & Murray, H. W. (2004) · Clinical Infectious Diseases · doi:10.1086/380971 · Cited by 189
Control of the leishmaniases. Report of a WHO Expert Committee.
(1990) · PubMed · Cited by 183
Drug discovery and development for neglected diseases: the DNDi model
Ioset, J.-R., & Chatelain (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s16381 · Cited by 182
Piscopo, T. V., & Azzopardi, C. M. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.047340corr1 · Cited by 180
Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds
Siqueira-Neto, J. L., Song, O., Oh, H. L., Sohn, J., Yang, G., Nam, J., Jang, J., Cechetto, J. D., Lee, C. B., Moon, S., et al. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000675 · Cited by 179
Self-citationThe beautiful cell: high-content screening in drug discovery
Bickle, M. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3788-3 · Cited by 176
Berman, J. D., Badaró, R. J. D. S., Thakur, C. P., Wasunna, K. M., Behbehani, K., Davidson, R. N., Kuzoe, F. A. S., Pang, L. W., Weerasuriya, K., & Bryceson, A. D. M. (1998) · Europe PMC (PubMed Central) · Cited by 171
Zhou, Y., Messier, N., Ouellette, M., Rosen, B. P., & Mukhopadhyay, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404383200 · Cited by 161
Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach
Crowther, G. J., Shanmugam, D., Carmona, S. J., Doyle, M., Hertz‐Fowler, C., Berriman, M., Nwaka, S., Ralph, S. A., Roos, D. S., Voorhis, W. C. V., et al. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000804 · Cited by 159
DENTON, H., McGregor, J. C., & Coombs, G. H. (2004) · Biochemical Journal · doi:10.1042/bj20040283 · Cited by 155
A PHASE II DOSE-INCREASING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN KENYA
Wasunna, M. K., RASHID, J. R., Mbui, J., Kirigi, G., Kinoti, D., Lodenyo, H. A., Felton, J. M., SABIN, A. J., & HORTON, J. (2005) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.871 · Cited by 150
Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India
Bhattacharya, S., Jha, T. K., Sundar, S., Thakur, C. P., Engel, J., SINDERMANN, H., Junge, K., Karbwang, J., Bryceson, A. D. M., & Berman, J. D. (2004) · Clinical Infectious Diseases · doi:10.1086/380638 · Cited by 145
Miltefosine Promotes IFN-γ-Dominated Anti-Leishmanial Immune Response
Wadhone, P., Maiti, M., Agrawal-Rajput, R., Kamat, V., Martin, S., & Saha, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803859 · Cited by 125
Nieto, A., Domínguez‐Bernal, G., Orden, J. A., de la Fuente, R., Madrid-Elena, N., & Carrión, J. (2011) · Veterinary Research · doi:10.1186/1297-9716-42-39 · Cited by 121
Lepesheva, G. I., & Waterman, M. R. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796575902 · Cited by 120
Rochette, A., Raymond, F., Corbeil, J., Ouellette, M., & Papadopoulou, B. (2009) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2008.12.012 · Cited by 113
High-content screening moves to the front of the line
Haney, S. A., LaPan, P., Pan, J., & Zhang, J. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.015 · Cited by 106
Cell-based high-content screening of small-molecule libraries
Korn, K., & Krausz, E. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.08.030 · Cited by 104
A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA
JHA, T. K., SUNDAR, S., THAKUR, C. P., Felton, J. M., SABIN, A. J., & HORTON, J. (2005) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2005.73.1005 · Cited by 103
Recent advances and controversies in adult cardiopulmonary resuscitation
Ibrahim, W. H. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2007.057133 · Cited by 102
Putrescine and spermidine transport in Leishmania
Basselin, M., Coombs, G. H., & Barrett, M. P. (2000) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(00)00234-6 · Cited by 95
A new antifungal antibiotic, amphotericin B.
OURA, M., Th, S., & WRIGHT, E. T. (1955) · PubMed · Cited by 92
Sharlow, E. R., Close, D. A., Shun, T., Leimgruber, S., Reed, R., Mustata, G. I., Wipf, P., Johnson, J. D., O’Neil, M. T., Grögl, M., et al. (2009) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000540 · Cited by 80
Osorio, E. Y., Travi, B. L., Renslo, A. R., Peniche, A. G., & Melby, P. C. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000962 · Cited by 79
Carvalho, L., Luque-Ortega, J. R., López-Martín, C., Castanys, S., Rivas, L., & Gamarro, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00520-11 · Cited by 78
Drug Development and the FDA's Critical Path Initiative
Woosley, R. L., & Cossman, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100014 · Cited by 76
Hellerstein, M. K. (2007) · Metabolic Engineering · doi:10.1016/j.ymben.2007.09.003 · Cited by 56
Fj, M. (1964) · PubMed · Cited by 44
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Parasitic Infections
Edwards, G., & Krishna, S. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1113-9 · Cited by 34
Cited by
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 355
Metadata
- Authors
- Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L.
- Venue
- International Journal for Parasitology: Drugs and Drug Resistance
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 2
- Pages
- 11-19
- ISSN
- 2211-3207 (ISSN-L)
- OpenAlex
- W2145904172
- Cited by
- 294
- References
- 51
- FWCI
- 18.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.